The DOI matches its Crossref record; 189 of the 189 references it cites were found in a registry or an index.
CD44: A Multifunctional Mediator of Cancer Progression
Open accessAbstract
CD44, a non-kinase cell surface transmembrane glycoprotein, has been widely implicated as a cancer stem cell (CSC) marker in several cancers. Cells overexpressing CD44 possess several CSC traits, such as self-renewal and epithelial-mesenchymal transition (EMT) capability, as well as a resistance to chemo- and radiotherapy. The CD44 gene regularly undergoes alternative splicing, resulting in the standard (CD44s) and variant (CD44v) isoforms. The interaction of such isoforms with ligands, particularly hyaluronic acid (HA), osteopontin (OPN) and matrix metalloproteinases (MMPs), drive numerous cancer-associated signalling. However, there are contradictory results regarding whether high or low CD44 expression is associated with worsening clinicopathological features, such as a higher tumour histological grade, advanced tumour stage and poorer survival rates. Nonetheless, high CD44 expression significantly contributes to enhanced tumourigenic mechanisms, such as cell proliferation, metastasis, invasion, migration and stemness; hence, CD44 is an important clinical target. This review summarises current research regarding the different CD44 isoform structures and their roles and functions in supporting tumourigenesis and discusses CD44 expression regulation, CD44-signalling pathways and interactions involved in cancer development. The clinical significance and prognostic value of CD44 and the potential of CD44 as a therapeutic target in cancer are also addressed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Chetty, C., Vanamala, S. K., Gondi, C. S., Dinh, D. H., Gujrati, M., & Rao, J. S. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.10.008 · Cited by 133
RetractedHuang, C., Yoon, C., Zhou, X., Zhou, Y., Zhou, W., Liu, H., Yang, X., Lü, J., Lee, S. Y., & Huang, K. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2448-6 · Cited by 56
RetractedRETRACTED ARTICLE: Correlation of CD44v6 expression with ovarian cancer progression and recurrence
Shi, J., Zhou, Z., Di, W. J., & Li, N. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-182 · Cited by 54
RetractedRemodelling the extracellular matrix in development and disease
Bonnans, C., Chou, J., & Werb, Z. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3904 · Cited by 4,367 · cited 1×
“Once it is removed by either knocking down HAS2 or overexpressing the HA-degrading enzyme, HYAL2, naked mole-rat cells become susceptible to malignant transformation and easily form tumours [145,146].”
BackgroundThe β-Catenin/TCF-4 Complex Imposes a Crypt Progenitor Phenotype on Colorectal Cancer Cells
van de Wetering, M., Sancho, E., Verweij, C., de Lau, W., Oving, I., Hurlstone, A., van der Horn, K., Batlle, E., Coudreuse, D., Haramis, A.-P., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)01014-0 · Cited by 2,030
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44
Liu, C., Kelnar, K., Liu, B., Chen, X., Calhoun-Davis, T., Li, H., Patrawala, L., Yan, H., Jeter, C., Honorio, S., et al. (2011) · Nature Medicine · doi:10.1038/nm.2284 · Cited by 1,400
The biology and role of CD44 in cancer progression: Therapeutic implications
Chen, C., Zhao, S., Karnad, A., & Freeman, J. W. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0605-5 · Cited by 1,245
Screaton, G. R., Bell, M. V., Jackson, D. G., Cornelis, F. B., Gerth, U., & Bell, J. I. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.24.12160 · Cited by 1,015
Misra, S., Hascall, V. C., Markwald, R. R., & Ghatak, S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00201 · Cited by 830
Membrane-Type 1 Matrix Metalloproteinase Cleaves Cd44 and Promotes Cell Migration
Kajita, M., Itoh, Y., Chiba, T., Mori, H., Okada, A., Kinoh, H., & Seiki, M. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.153.5.893 · Cited by 746
Yu, Q., & Stamenkovic, I. (1999) · Genes & Development · doi:10.1101/gad.13.1.35 · Cited by 713
Goodison, S., Urquidi, V, & Tarin, D. (1999) · Molecular Pathology · doi:10.1136/mp.52.4.189 · Cited by 679
Stamenkovic, I., Amiot, M., Pesando, J. M., & Seed, B. (1989) · Cell · doi:10.1016/0092-8674(89)90638-7 · Cited by 672
Brown, R. L., Reinke, L. M., Damerow, M. S., Perez, D., Chodosh, L. A., Yang, J., & Cheng, C. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44540 · Cited by 631
The Nature and Significance of Osteopontin
Butler, W. T. (1989) · Connective Tissue Research · doi:10.3109/03008208909002412 · Cited by 560
Pietras, A., Katz, A. M., Ekström, E. J., Wee, B., Halliday, J. J., Pitter, K. L., Werbeck, J. L., Amankulor, N. M., Huse, J. T., & Holland, E. C. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.01.005 · Cited by 540
Hyaluronan–CD44 interactions as potential targets for cancer therapy
Misra, S., Heldin, P., Hascall, V. C., Karamanos, N. K., Skandalis, S. S., Markwald, R. R., & Ghatak, S. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08071.x · Cited by 494
CD44, a therapeutic target for metastasising tumours
Orian-Rousseau, V. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.024 · Cited by 474
Godar, S., Ince, T. A., Bell, G. W., Feldser, D., Donaher, J. L., Bergh, J., Liu, A., Miu, K., Watnick, R. S., Reinhardt, F., et al. (2008) · Cell · doi:10.1016/j.cell.2008.06.006 · Cited by 456
Expression of CD44 in Apc and TcfMutant Mice Implies Regulation by the WNT Pathway
Wielenga, V. J. M., Smits, R., Korinek, V., Smit, L., Kielman, M., Fodde, R., Clevers, H., & Pals, S. T. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65297-2 · Cited by 433
Cell Adhesion and Matrix Stiffness: Coordinating Cancer Cell Invasion and Metastasis
Gkretsi, V., & Stylianopoulos, T. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00145 · Cited by 390
Liu, X., Taftaf, R., Kawaguchi, M., Chang, Y.-F., Chen, W., Entenberg, D., Zhang, Y., Gerratana, L., Huang, S., Patel, D. B., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0065 · Cited by 390
Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell
Yae, T., Tsuchihashi, K., Ishimoto, T., Motohara, T., Yoshikawa, M., Yoshida, G. J., Wada, T., Masuko, T., Mogushi, K., Tanaka, H., et al. (2012) · Nature Communications · doi:10.1038/ncomms1892 · Cited by 383
An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion
Klement, J. D., Paschall, A. V., Redd, P. S., Ibrahim, M. L., Lu, C., Yang, D., Celis, E., Abrams, S. I., Ozato, K., & Liu, K. (2018) · Journal of Clinical Investigation · doi:10.1172/jci123360 · Cited by 368
Hyaluronan-CD44 Interactions in Cancer: Paradoxes and Possibilities
Toole, B. P. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0479 · Cited by 362
Li, J., & Zhou, B. P. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-49 · Cited by 339
Gobin, E., Bagwell, K., Wagner, J., Mysona, D., Sandirasegarane, S., Smith, N., Bai, S., Sharma, A., Schleifer, R., & She, J.-X. (2019) · BMC Cancer · doi:10.1186/s12885-019-5768-0 · Cited by 338
Eliaz, R. E., & Szoka, F. C. (2001) · PubMed · Cited by 330
The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer
Thapa, R., & Wilson, G. D. (2016) · Stem Cells International · doi:10.1155/2016/2087204 · Cited by 312
Splicing choice from ten variant exons establishes CD44 variability
Tölg, C., Hofmann‐Apitius, M., Herrlich, P. A., & Ponta, H. (1993) · Nucleic Acids Research · doi:10.1093/nar/21.5.1225 · Cited by 279
Expression of CD44R1 adhesion molecule in colon carcinomas and metastases
Tanabe, K. K., Ellis, L. M., & Saya, H. (1993) · The Lancet · doi:10.1016/0140-6736(93)90490-8 · Cited by 271
CD44: More than a mere stem cell marker
Morath, I., Hartmann, T. N., & Orian-Rousseau, V. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.09.009 · Cited by 248
CHUNG, S. S., & Vadgama, J. V. (2015) · PubMed · Cited by 236
Cheng, W., Liu, T., Wan, X., Gao, Y., & Wang, H. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08589.x · Cited by 229
Liu, C., Liu, R., Zhang, D., Deng, Q., Liu, B., Chao, H.-P., Rycaj, K., Takata, Y., Lin, K., Lu, Y., et al. (2017) · Nature Communications · doi:10.1038/ncomms14270 · Cited by 228
CD44 splice isoform switching determines breast cancer stem cell state
Zhang, H., Brown, R. L., Wei, Y., Zhao, P., Liu, S., Liu, X., Deng, Y., Hu, X., Zhang, J., Gao, X. D., et al. (2019) · Genes & Development · doi:10.1101/gad.319889.118 · Cited by 228
Hiraga, T., Ito, S., & Nakamura, H. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3801 · Cited by 226
Analysis of CD44-Hyaluronan Interactions in an Artificial Membrane System
Wolny, P. M., Banerji, S., Gounou, C., Brisson, A. R., Day, A. J., Jackson, D. G., & Richter, R. P. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.137562 · Cited by 224
ERK1/2 Regulation of CD44 Modulates Oral Cancer Aggressiveness
Judd, N. P., Winkler, A. E., Murillo-Sauca, O., Brotman, J. J., Law, J. H., Lewis, J. S., Dunn, G. P., Bui, J. D., Sunwoo, J. B., & Uppaluri, R. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1831 · Cited by 221
Mima, K., Okabe, H., Ishimoto, T., Hayashi, H., Nakagawa, S., Kuroki, H., Watanabe, M., Beppu, T., Tamada, M., Nagano, O., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0299 · Cited by 215
CD44v8-10 Is a Cancer-Specific Marker for Gastric Cancer Stem Cells
Lau, W. M., Teng, E., Chong, H. S., Lopez, K. A. P., Tay, A. Y. L., Salto-Tellez, M., Shabbir, A., So, J. B. Y., & Chan, S. L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2309 · Cited by 206
Olsson, E., Honeth, G., Bendahl, P.-O., Saal, L. H., Gruvberger-Saal, S., Ringnér, M., Vallon-Christersson, J., Jönsson, G., Holm, K., Lövgren, K., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-418 · Cited by 204
Roles and targeting of the HAS/hyaluronan/CD44 molecular system in cancer
Karousou, E., Misra, S., Ghatak, S., Dobra, K., Götte, M., Vigetti, D., Passi, A., Karamanos, N. K., & Skandalis, S. S. (2017) · Matrix Biology · doi:10.1016/j.matbio.2016.10.001 · Cited by 203
Kim, B. N., Ahn, D. H., Kang, N., Yeo, C. D., Kim, Y. K., Lee, K. Y., Kim, T.-J., Lee, S. H., Park, M. S., Yim, H. W., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-67325-7 · Cited by 199
Regulation of alternative splicing of CD44 in cancer
Prochazka, L., Tesarik, R., & Turanek, J. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.07.011 · Cited by 198
CD44 is the Principal Mediator of Hyaluronic-Acid-Induced Melanoma Cell Proliferation
Assmann, V., Fieber, C., Herrlich, P., Hofmann, M., Termeer, C. C., Ahrens, T., & Simon, J. C. (2001) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2001.00236.x · Cited by 186
Significance of CD44 expression in head and neck cancer: a systemic review and meta-analysis
Chen, J., Zhou, J., Lu, J., Xiong, H., Shi, X., & Gong, L. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-15 · Cited by 184
Arabi, L., Badiee, A., Mosaffa, F., & Jaafari, M. R. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.044 · Cited by 183
Muntimadugu, E., Kumar, R., Saladi, S., Rafeeqi, T. A., & Khan, W. (2016) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2016.03.075 · Cited by 181
Zhao, S., Chen, C., Chang, K., Karnad, A., Jagirdar, J., Kumar, A. P., & Freeman, J. W. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3115 · Cited by 173
Cancer Cell CD44 Mediates Macrophage/Monocyte-Driven Regulation of Head and Neck Cancer Stem Cells
Gomez, K. E., Wu, F., Keysar, S. B., Morton, J. J., Miller, B., Chimed, T.-S., Le, P. N., Nieto, C., Chowdhury, F. N., Tyagi, A., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1079 · Cited by 170
Erdoğan, S., Doğanlar, O., Doğanlar, Z. B., Serttas, R., Turkekul, K., Dıbırdık, İ., & Bılır, A. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.08.019 · Cited by 169
CD44 variant 6 is associated with prostate cancer metastasis and chemo‐/radioresistance
Ni, J., Cozzi, P. J., Hao, J., Beretov, J., Chang, L., Duan, W., Shigdar, S. L., Delprado, W., Graham, P., Bucci, J. A., et al. (2014) · The Prostate · doi:10.1002/pros.22775 · Cited by 161
Bao, W., Fu, H., Xie, Q., Wang, L., Zhang, R., Guo, Z., Zhao, J., Meng, Y., Ren, X., Wang, T., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.08.050 · Cited by 161
Molecular implications of MUC5AC-CD44 axis in colorectal cancer progression and chemoresistance
Pothuraju, R., Rachagani, S., Krishn, S. R., Chaudhary, S., Nimmakayala, R. K., Siddiqui, J. A., Ganguly, K., Lakshmanan, I., Cox, J. L., Mallya, K., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01156-y · Cited by 160
Proteases in brain tumour progression
Levičar, N., Nutall, R. K., & Lah, T. T. (2003) · Acta Neurochirurgica · doi:10.1007/s00701-003-0097-z · Cited by 159
Yang, X., lyer, A. K., Singh, A., Choy, E., Hornicek, F. J., Amiji, M. M., & Duan, Z. (2015) · Scientific Reports · doi:10.1038/srep08509 · Cited by 158
Bourguignon, L., Zhu, H., Shao, L., Zhu, D., & Chen, Y.-W. (1999) · Cell Motility and the Cytoskeleton · doi:10.1002/(sici)1097-0169(1999)43:4<269::aid-cm1>3.0.co;2-5 · Cited by 158
Porter, C. E., Shaw, A. R., Jung, Y., Yip, T., Castro, P. D., Sandulache, V. C., Sikora, A. G., Gottschalk, S. M., Ittman, M. M., Brenner, M. K., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.02.016 · Cited by 148
Evaluating the Efficiency of Hyaluronic Acid for Tumor Targeting via CD44
Spadea, A., Rosa, J. M. R. D. L., Tirella, A., Ashford, M. B., Williams, K. J., Stratford, I. J., Tirelli, N., & Mehibel, M. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00083 · Cited by 147
CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion
Kim, H. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1453 · Cited by 146
CD44v6 engages in colorectal cancer progression
Ma, L., Dong, L., & Chang, P. (2019) · Cell Death and Disease · doi:10.1038/s41419-018-1265-7 · Cited by 145
A positive feedback loop couples Ras activation and CD44 alternative splicingPreprint
Cheng, C., Yaffe, M. B., & Sharp, P. A. (2006) · Genes & Development · doi:10.1101/gad.1430906 · Cited by 144
Methylation of the CD44 metastasis suppressor gene in human prostate cancer.
Lou, W., Krill, D., Dhir, R., Becich, M. J., Dong, J., Frierson, H. F., Isaacs, W. B., Isaacs, J. T., & Gao, A. C. (1999) · PubMed · Cited by 142
Zeilstra, J., Joosten, S. P. J., van Andel, H., Tölg, C., Berns, A. J. M., Snoek, M., van de Wetering, M., Spaargaren, M., Clevers, H. C., & Pals, S. T. (2013) · Oncogene · doi:10.1038/onc.2012.611 · Cited by 140
Hyaluronan-CD44 axis orchestrates cancer stem cell functions
Skandalis, S. S., Karalis, T. T., Chatzopoulos, A., & Karamanos, N. K. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109377 · Cited by 138
Increased expression of MMP-2 and MMP-9 indicates poor prognosis in glioma recurrence
Zhou, W., Yu, X., Sun, S., Zhang, X., Yang, W., Zhang, J., Zhang, X., & Jiang, Z. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109369 · Cited by 137
NF-κB Affects Proliferation and Invasiveness of Breast Cancer Cells by Regulating CD44 Expression
Smith, S. M., Lyu, Y. L., & Cai, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106966 · Cited by 134
Orian‐Rousseau, V., & Sleeman, J. P. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-800092-2.00009-5 · Cited by 131
Nam, K., Oh, S., Lee, K., Yoo, S., & Shin, I. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.05.002 · Cited by 128
Markers of pancreatic cancer stem cells and their clinical and therapeutic implications
Gzil, A., Zarębska, I., Bursiewicz, W., Antosik, P., Grzanka, D., & Szylberg, Ł. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-05058-1 · Cited by 124
Johansson, E., Grassi, E. S., Pantazopoulou, V., Tong, B., Lindgren, D., Berg, T. J., Pietras, E. J., Axelson, H., & Pietras, A. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.049 · Cited by 121
Fernando, J., Malfettone, A., Cepeda, E. B., Vilarrasa‐Blasi, R., Bertrán, E., Raimondi, G., Fabra, À., Alvarez, A. M., Fernández‐Salguero, P. M., Fernández‐Rodríguez, C., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29097 · Cited by 119
CD44 increases the efficiency of distant metastasis of breast cancer
McFarlane, S., Coulter, J. A., Tibbits, P., O’Grady, A., McFarlane, C., Montgomery, N., Hill, A., McCarthy, H. O., Young, L. S., Kay, E. W., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3410 · Cited by 119
Naked mole-rat very-high-molecular-mass hyaluronan exhibits superior cytoprotective properties
Takasugi, M., Firsanov, D., Tombline, G., Ning, H., Ablaeva, J., Seluanov, A., & Gorbunova, V. A. (2020) · Nature Communications · doi:10.1038/s41467-020-16050-w · Cited by 119
Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44
Zhang, S., Wu, C. C. N., Fecteau, J.-F., Cui, B., Chen, L., Zhang, L., Wu, R., Rassenti, L. Z., Lao, F. S., Weigand, S., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221841110 · Cited by 118
Hong, Y., Qin, H., Li, Y., Zhang, Y., Zhuang, X., Liu, L., Lü, K., Li, L., Deng, X., Liu, F., et al. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28588 · Cited by 117
Khan, S. A., Cook, A. C., Kappil, M., Günthert, U., Chambers, A., Tuck, A., & Denhardt, D. (2006) · Clinical and Experimental Metastasis · doi:10.1007/s10585-006-9007-0 · Cited by 111
CD44 isoforms during differentiation and development
Ruíz, P., Schwärzler, C., & Günthert, U. (1995) · BioEssays · doi:10.1002/bies.950170106 · Cited by 110
A mode of cell adhesion and migration facilitated by CD44-dependent microtentacles
Wolf, K. J., Shukla, P. D., Springer, K. S., Lee, S., Coombes, J. D., Choy, C. K., Kenny, S. J., Xu, K., & Kumar, S. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1914294117 · Cited by 108
Shitara, K., Doi, T., Nagano, O., Imamura, C. K., Ozeki, T., Ishii, Y., Tsuchihashi, K., Takahashi, S., Nakajima, T. E., Hironaka, S., et al. (2016) · Gastric Cancer · doi:10.1007/s10120-016-0610-8 · Cited by 103
Kreger, S. T., & Voytik‐Harbin, S. L. (2009) · Matrix Biology · doi:10.1016/j.matbio.2009.05.001 · Cited by 102
The Prognostic and Clinical Value of CD44 in Colorectal Cancer: A Meta-Analysis
Wang, Z., Tang, Y., Xie, L., Huang, A., Xue, C., Gu, Z., Wang, K., & Zong, S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00309 · Cited by 100
Epigenetic Regulation of Cancer Stem Cell Genes in Triple-Negative Breast Cancer
Kagara, N., Huynh, K. T., Kuo, C. T., Okano, H., Sim, M., Elashoff, D. A., Chong, K. K., Giuliano, A. E., & Hoon, D. S. �. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.03.019 · Cited by 99
Novel CD44-downstream signaling pathways mediating breast tumor invasion
Ouhtit, A., Rizeq, B. R., Saleh, H. A., Rahman, M. M., & Zayed, H. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.23586 · Cited by 96
Lai, C., Lin, C., Liao, W., Hour, T., Wang, H., & Chuu, C. (2019) · Cells · doi:10.3390/cells8040295 · Cited by 95
Kolb, A., Kleeff, J. H., Guweidhi, A., Esposito, I., Giese, N., Adwan, H., Giese, T., Büchler, M. W., Berger, M. R., & Friess, H. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.7.1821 · Cited by 94
CD44 isoform expression in primary and metastatic pancreatic adenocarcinoma.
Rall, C., & Rustgi, A. K. (1995) · PubMed · Cited by 94
CD44(+) tumor cells promote early angiogenesis in head and neck squamous cell carcinoma
Ludwig, N., Szczepański, M. J., Głuszko, A., Szafarowski, T., Azambuja, J. H., Dolg, L., Gellrich, N., Kampmann, A., Whiteside, T. L., & Zimmerer, R. M. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.10.010 · Cited by 92
Understanding Glioblastoma Biomarkers: Knocking a Mountain with a Hammer
Mesrati, M. H., Behrooz, A. B., Abuhamad, A. Y., & Syahir, A. (2020) · Cells · doi:10.3390/cells9051236 · Cited by 91
Self-citationCD44 promotes cell proliferation in non-small cell lung cancer
Hu, B., Ma, Y., Yang, Y., Zhang, L., Han, H., & Chen, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.8051 · Cited by 90
Ishimoto, T., Sugihara, H., Watanabe, M., Sawayama, H., Iwatsuki, M., Baba, Y., Okabe, H., Hidaka, K., Yokoyama, N., Miyake, K., et al. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt402 · Cited by 86
Wu, K., Xu, H., Yuan, X., Tian, Y., Liu, Y., Liu, Q., Wu, H. K., & Wu, G. S. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s97192 · Cited by 86
CD44 Proteolysis Increases CREB Phosphorylation and Sustains Proliferation of Thyroid Cancer Cells
Falco, V. D., Tamburrino, A., Ventre, S., Castellone, M. D., Malek, M., Manié, S. N., & Santoro, M. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3320 · Cited by 84
Bourguignon, L., Earle, C., & Shiina, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091849 · Cited by 84
Montgomery, N., Hill, A., McFarlane, S., Neisen, J., O’Grady, A., Conlon, S. J., Jirström, K., Kay, E. W., & Waugh, D. J. J. (2012) · Breast Cancer Research · doi:10.1186/bcr3199 · Cited by 83
Expression of CD44 in pancreatic cancer and its significance.
Li, X.-P., Zhang, X.-W., Zheng, L., & Guo, W.-J. (2015) · Europe PMC (PubMed Central) · Cited by 82
Kinugasa, H., Whelan, K. A., Tanaka, K., Natsuizaka, M., Long, A., Guo, A. J., Chang, S., Kagawa, S., Srinivasan, S., Guha, M., et al. (2015) · Oncogene · doi:10.1038/onc.2014.449 · Cited by 82
CD44 correlates with clinicopathological characteristics and is upregulated by EGFR in breast cancer
Xu, H., Wu, K., Tian, Y., Liu, Q., Han, N., Yuan, X., Zhang, L., Wu, G. S., & Wu, K. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3639 · Cited by 82
An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression
Ahmed, M., Sottnik, J. L., Dancik, G. M., Sahu, D., Hansel, D. E., Theodorescu, D., & Schwartz, M. A. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.08.002 · Cited by 81
CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice
Porcellini, S., Asperti, C., Corna, S., Cicoria, E., Valtolina, V., Stornaiuolo, A., Valentinis, B., Bordignon, C., & Traversari, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00099 · Cited by 80
The prognostic role of the cancer stem cell marker CD44 in ovarian cancer: a meta-analysis
Lin, J.-Y., & Ding, D. (2017) · Cancer Cell International · doi:10.1186/s12935-016-0376-4 · Cited by 78
CD44v/CD44s expression patterns are associated with the survival of pancreatic carcinoma patients
Li, Z., Chen, K., Jiang, P., Zhang, X., Li, X., & Li, Z. (2014) · Diagnostic Pathology · doi:10.1186/1746-1596-9-79 · Cited by 77
ATDC induces an invasive switch in KRAS-induced pancreatic tumorigenesis
Wang, L., Yang, H., Abel, E. V., Ney, G. M., Palmbos, P. L., Bednar, F., Zhang, Y., Leflein, J., Waghray, M., Owens, S. R., et al. (2015) · Genes & Development · doi:10.1101/gad.253591.114 · Cited by 76
Akt Signaling Is Sustained by a CD44 Splice Isoform–Mediated Positive Feedback Loop
Liu, S., & Cheng, C. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2545 · Cited by 76
The CD44s splice isoform is a central mediator for invadopodia activity
Zhao, P., Xu, Y., Wei, Y., Qiu, Q., Chew, T., Kang, Y., & Cheng, C. (2016) · Journal of Cell Science · doi:10.1242/jcs.171959 · Cited by 75
CD44 regulates prostate cancer proliferation, invasion and migration via PDK1 and PFKFB4
Li, W., Li, Q., Lin, J., Huang, G., Hao, N., Wei, X., Wang, W., & Liang, J. (2017) · Oncotarget · doi:10.18632/oncotarget.17821 · Cited by 74
Boxberg, M., Götz, C., Haidari, S., Dorfner, C., Jesinghaus, M., Drecoll, E., Boskov, M., Wolff, K. D., Weichert, W., Haller, B., et al. (2018) · Histopathology · doi:10.1111/his.13496 · Cited by 74
Masaki, T., Goto, A., Sugiyama, M., Matsuoka, H., Abe, N., Sakamoto, A., & Atomi, Y. (2001) · Cancer · Cited by 71
Thanee, M., Loilome, W., Techasen, A., Sugihara, E., Okazaki, S., Abe, S., Ueda, S., Masuko, T., Namwat, N., Khuntikeo, N., et al. (2016) · Cancer Science · doi:10.1111/cas.12967 · Cited by 70
Calvete, J., Larrinaga, G., Errarte, P., Martín, A. M., Dotor, A. M., Esquinas, C., Nunes‐Xavier, C. E., Pulido, R., Lopez, J. I., & Angulo, J. C. (2019) · Human Pathology · doi:10.1016/j.humpath.2019.07.002 · Cited by 70
Chen, D., Li, D., Xu, X., Qiu, S., Luo, S., Qiu, E., Rong, Z., Zhang, J., & Zheng, D. (2019) · Journal of Cancer · doi:10.7150/jca.31487 · Cited by 70
Prognostic value of CD44 splice variants in human stage III cervical cancer
Kainz, C., Kohlberger, P., Tempfer, C. M., Sliutz, G., Gitsch, G., Reinthaller, A., & Breitenecker, G. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)00353-k · Cited by 69
Chen, Q., Gu, M., Cai, Z., Zhao, H., Sun, S., Liu, C., Zhan, M., Chen, Y., & Wang, Z. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03544-5 · Cited by 69
Dzobo, K., & Sinkala, M. (2021) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2021.0025 · Cited by 69
Fanelli, M. F., Chinen, L. T. D., Begnami, M. D., da Costa, W. L., Fregnami, J. H. T., Soares, F. A., & MONTAGNINI, A. L. (2012) · Histopathology · doi:10.1111/j.1365-2559.2011.04139.x · Cited by 68
Okabe, H., Ishimoto, T., Mima, K., Nakagawa, S., Hayashi, H., Kuroki, H., Imai, K., Nitta, H., Saito, S., Hashimoto, D., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.759 · Cited by 67
Iida, N., & Bourguignon, L. (1997) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199705)171:2<152::aid-jcp5>3.0.co;2-n · Cited by 66
Structure, function and role of CD44 in neoplasia
Mishra, M., Chandavarkar, V., Sharma, R., & Bhargava, D. (2019) · Journal of Oral and Maxillofacial Pathology · doi:10.4103/jomfp.jomfp_246_18 · Cited by 65
Yang, G., Fan, J., Xu, Y., Qiu, S., Yang, X., Shi, G., Wu, B., Dai, Z., Liu, Y., Tang, Z., et al. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0081 · Cited by 64
A switch from CD44+ cell to EMT cell drives the metastasis of prostate cancer
Shang, Z., Cai, Q., Zhang, M., Zhu, S., Ma, Y., Sun, L., Jiang, N., Tian, J., Niu, X., Chen, J., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2841 · Cited by 63
Sapudom, J., Ullm, F., Martin, S., Kalbitzer, L., Naab, J., Möller, S., Schnabelrauch, M., Anderegg, U., Schmidt, S., & Pompe, T. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.12.026 · Cited by 63
Bánky, B., Rásó‐Barnett, L., Barbai, T., Tı́már, J., Becságh, P., & Rásó, E. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-83 · Cited by 62
Yang, Z., Luo, H., Cao, Z., Chen, Y., Gao, J., Li, Y., Jiang, Q. Y., Xu, R., & Liu, J. (2016) · Nanoscale · doi:10.1039/c6nr01749e · Cited by 62
Prognostic significance of CD44 variant 2 upregulation in colorectal cancer
Ozawa, M., Ichikawa, Y., Zheng, Y.-W., Oshima, T., Miyata, H., Nakazawa, K., Guan, H.-B., Shiozawa, M., Akaike, M., Watanabe, K., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.253 · Cited by 61
Co-localization and crosstalk between CD44 and RHAMM depend on hyaluronan presentation
Carvalho, A. M., da Costa, D. S., Paulo, P. M. R., Reis, R. L., & Pashkuleva, I. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.10.024 · Cited by 61
miR-221 regulates CD44 in hepatocellular carcinoma through the PI3K-AKT-mTOR pathway
Kim, J., Jiang, J., Badawi, M. A., & Schmittgen, T. D. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.04.121 · Cited by 60
Tirella, A., Kloc-Muniak, K., Good, L., Ridden, J., Ashford, M., Puri, S., & Tirelli, N. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.02.032 · Cited by 60
CD44 promotes Kras-dependent lung adenocarcinoma
Zhao, P., Damerow, M. S., Stern, P., et al. (2012) · Oncogene · doi:10.1038/onc.2012.542 · Cited by 58
Expression of CD44 Variants and Its Association with Survival in Pancreatic Cancer
Gotoda, T., Matsumura, Y., Kondo, H. G., Saitoh, D., Shimada, Y., Kosuge, T., Kanai, Y., & Kakizoe, T. (1998) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1998.tb00493.x · Cited by 58
Hagiwara, M., Kikuchi, E., Tanaka, N., Kosaka, T., Mikami, S., Saya, H., & Oya, M. (2018) · BMC Cancer · doi:10.1186/s12885-018-3988-3 · Cited by 58
CD44 is overexpressed and correlated with tumor progression in gallbladder cancer
He, Y., Xue, C., Yu, Y. H., Chen, J., Chen, X., Ren, F., Ren, Z., Cui, G., & Sun, R. (2018) · Cancer Management and Research · doi:10.2147/cmar.s175681 · Cited by 58
Identification of a Panel of Genes as a Prognostic Biomarker for Glioblastoma
Wang, F., Zheng, Z., Guan, J., Qi, D., Zhou, S., Shen, X., Wang, F., Wenkert, D., Kirmani, B. F., Solouki, T., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.10.024 · Cited by 58
Zhou, J., Du, Y., Lu, Y., Luan, B., Xu, C., Yu, Y., & Zhao, H. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00802 · Cited by 58
Silencing of CD44 Expression in Prostate Cancer by Hypermethylation of the CD44 Promoter Region
Verkaik, N. S., van Steenbrugge, G. J., van Weerden, W. M., Bussemakers, M. J. G., & van der Kwast, T. (2000) · Laboratory Investigation · doi:10.1038/labinvest.3780137 · Cited by 57
CD44 targets Wnt/β-catenin pathway to mediate the proliferation of K562 cells
Chang, G., Zhang, H., Wang, J., Zhang, Y., Xu, H. Z., Wang, C., Zhang, H., Ma, L., Li, Q., & Pang, T. (2013) · Cancer Cell International · doi:10.1186/1475-2867-13-117 · Cited by 57
Yanamoto, S., Yamada, S., Takahashi, H., Naruse, T., Matsushita, Y., Ikeda, H., Shiraishi, T., Seki, S., Fujita, S., Ikeda, T., et al. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2289 · Cited by 57
FOXP3 suppresses breast cancer metastasis through downregulation of CD44
Zhang, C., Xu, Y., Hao, Q., Wang, S., Li, H., Li, J., Gao, Y., Li, M., Li, W., Xue, X., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29482 · Cited by 54
Taghipour-Sabzevar, V., Sharifi, T., Bagheri‐Khoulenjani, S., Goodarzi, V., Kooshki, H., Halabian, R., & Moghaddam, M. M. (2020) · Journal of Nanoparticle Research · doi:10.1007/s11051-020-04838-2 · Cited by 54
Prognostic Significance of CD24 and CD44 in Breast Cancer: A Meta-Analysis
Wang, Z., Wang, Q., Wang, Q., Wang, Y., & Chen, J. (2016) · The International Journal of Biological Markers · doi:10.5301/jbm.5000224 · Cited by 53
Mohamed, S. Y., Kaf, R. M., Ahmed, M. M., Elwan, A., Ashour, H. R., & Ibrahim, A. E. S. T. (2018) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-018-0156-6 · Cited by 53
Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells
Alhabbab, R. Y. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00312 · Cited by 53
Sapudom, J., Müller, C. D., Nguyen, K.-T., Martin, S., Anderegg, U., & Pompe, W. (2020) · Gels · doi:10.3390/gels6040033 · Cited by 50
Clinical significance of CD44 variant 9 expression as a prognostic indicator in bladder cancer
Kobayashi, K., Matsumoto, H., Matsuyama, H., Fujii, N., Inoue, R., Yamamoto, Y., & Nagao, K. (2016) · Oncology Reports · doi:10.3892/or.2016.5061 · Cited by 49
Internalized CD44s splice isoform attenuates EGFR degradation by targeting Rab7A
Wang, W., Zhang, H., Liu, S., Kim, C. K., Xu, Y., Hurley, L., Nishikawa, R., Nagane, M., Hu, B., Stegh, A. H., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1701289114 · Cited by 48
Morand, G. B., Ikenberg, K., Vital, D., Cardona, I., Moch, H., Stoeckli, S. J., & Huber, G. F. (2018) · Head & Neck · doi:10.1002/hed.25532 · Cited by 48
Yin, J., Zhang, H., Wu, X., Zhang, Y., Li, J., Shen, J., Zhao, Y., Xiao, Z., Lu, L., Huang, C.-L., et al. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4562 · Cited by 48
Cortes‐Dericks, L., & Schmid, R. A. (2017) · Respiratory Research · doi:10.1186/s12931-017-0546-5 · Cited by 47
Khayrani, A. C., Mahmud, H., Oo, A. K. K., Zahra, M. H., Oze, M., Du, J., Alam, M. J., Afify, S. M., Quora, H. A. A., Shigehiro, T., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051042 · Cited by 47
Senbanjo, L. T., Aljohani, H., Majumdar, S., & Chellaiah, M. A. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0395-6 · Cited by 47
DNA Aptamers against Exon v10 of CD44 Inhibit Breast Cancer Cell Migration
Iida, J., Clancy, R., Dorchak, J., Somiari, R. I., Somiari, S., Cutler, M. L., Mural, R., & Shriver, C. D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088712 · Cited by 46
MMP-14 and CD44 in Epithelial-to-Mesenchymal Transition (EMT) in ovarian cancer
Vos, M. C., Hollemans, E., Ezendam, N. P. M., Feijen, H., Boll, D., Pijlman, B. M., van der Putten, H. W. H. M., Klinkhamer, P. J. J. M., Kuppevelt, T. H. V., van der Wurff, A. A. M., et al. (2016) · Journal of Ovarian Research · doi:10.1186/s13048-016-0262-7 · Cited by 45
MicroRNA-143 targets CD44 to inhibit breast cancer progression and stem cell-like properties
Yang, Z., Chen, D., NIE, J., Zhou, S., WANG, J., TANG, Q., & Yang, X. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5194 · Cited by 44
Holah, N. S., Aiad, H. A. S., Asaad, N. Y., Elkhouly, E., & Lasheen, A. G. (2017) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2017/22671.9291 · Cited by 44
Reversion to an embryonic alternative splicing program enhances leukemia stem cell self-renewal
Holm, F., Hellqvist, E., Mason, C. N., Ali, S. A., Santos, N. P. D., Barrett, C. L., Chun, H.-J. E., Minden, M. D., Moore, R. A., Marra, M. A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1506943112 · Cited by 43
Lu, Y., Cheng, A., Lee, L., You, G.-R., Li, Y.-L., Chen, H.-Y., & Chang, J. T. (2017) · Scientific Reports · doi:10.1038/s41598-017-02058-8 · Cited by 42
Lee, J. R., Roh, J., Lee, S. M., Park, Y., Cho, K., Choi, S., Nam, S. Y., & Kim, S. Y. (2018) · Head & Neck · doi:10.1002/hed.25331 · Cited by 40
Nishino, M., Ozaki, M., Hegab, A. E., Hamamoto, J., Kagawa, S., Arai, D., Yasuda, H., Naoki, K., Soejima, K., Saya, H., et al. (2017) · Journal of Cancer · doi:10.7150/jca.19732 · Cited by 39
Tunable layer-by-layer films containing hyaluronic acid and their interactions with CD44
Amorim, S., Pashkuleva, I., Reis, C. A., Reis, R. L., & Pires, R. A. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb00407c · Cited by 39
Isoform switch of CD44 induces different chemotactic and tumorigenic ability in gallbladder cancer
Miwa, T., Nagata, T., 小島, 博., Sekine, S., & Okumura, T. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4063 · Cited by 38
Dzobo, K., Ganz, C., Thomford, N. E., & Senthebane, D. A. (2020) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2020.0185 · Cited by 38
The osteopontin-CD44 axis in hepatic cancer stem cells regulates IFN signaling and HCV replication
Shirasaki, T., Honda, M., Yamashita, T., Nio, K., Shimakami, T., Shimizu, R., Nakasyo, S., Murai, K., Shirasaki, N., Okada, H., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-31421-6 · Cited by 37
A reciprocal regulatory circuit between CD44 and FGFR2 via c-myc controls gastric cancer cell growth
Park, J., Kim, S. Y., Kim, H.-J., Kim, K., Choi, E. Y., & Kang, M.-S. (2016) · Oncotarget · doi:10.18632/oncotarget.8764 · Cited by 36
The CD44 standard isoform contributes to radioresistance of pancreatic cancer cells
Tsubouchi, K., Minami, K., Hayashi, N., Yokoyama, Y., Mori, S., Yamamoto, H., & Koizumi, M. (2017) · Journal of Radiation Research · doi:10.1093/jrr/rrx033 · Cited by 36
Zanjani, L. S., Madjd, Z., Abolhasani, M., Rasti, A., Fodstad, Ø., Andersson, Y., & Asgari, M. (2017) · Biomarkers in Medicine · doi:10.2217/bmm-2017-0142 · Cited by 36
Kim, S., Kil, W. H., Lee, J., Oh, S. J., Han, J., Jeon, M., Jung, T., Lee, S. K., Bae, S. Y., Lee, H., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.3514 · Cited by 33
Wang, H., Ye, X., Ju, Y., Cai, Z., Wang, X., Du, P., Zhang, M., Li, Y., & Cai, J. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s247836 · Cited by 33
Characterization of CD44 variant expression in head and neck squamous cell carcinomas
Spiegelberg, D., Kuku, G., Selvaraju, R. K., & Nestor, M. (2013) · Tumor Biology · doi:10.1007/s13277-013-1272-3 · Cited by 32
Hyaluronic acid-CD44 interactions promote BMP4/7-dependent Id1/3 expression in melanoma cells
Wu, R., Sedlmeier, G., Kyjacová, L., Schmaus, A., Philipp, J., Thiele, W., Garvalov, B. K., & Sleeman, J. P. (2018) · Scientific Reports · doi:10.1038/s41598-018-33337-7 · Cited by 32
Choi, E. S., Kim, H., Kim, H., Choi, Y., & Goh, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-05247-7 · Cited by 30
Lourenço, B. N., Springer, N. L., Ferreira, D. A., Oliveíra, C., Granja, P. L., & Fischbach, C. (2018) · Integrative Biology · doi:10.1039/c7ib00179g · Cited by 28
Carneiro, I. C., Vieira, F. Q., Lobo, J., Moreira-Barbosa, C., Menezes, F. D., Martins, A. T., Oliveira, J., Silva, R. A., Jerónimo, C., & Henrique, R. (2019) · Journal of Cancer · doi:10.7150/jca.34564 · Cited by 28
Qiu, Y., Hu, Y., Zhang, Z.-Y., Ye, L., Xu, F., Schneider, M. E., Ma, X., Du, Y., Zuo, X.-B., Zhou, F., et al. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1761-9 · Cited by 27
Kagami, T., Yamade, M., Suzuki, T., Uotani, T., Tani, S., Hamaya, Y., Iwaizumi, M., Osawa, S., Sugimoto, K., Baba, S., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26172 · Cited by 27
Diao, L., Shen, A., Yang, Y., Tao, J., & Hu, Y. (2019) · RSC Advances · doi:10.1039/c9ra08202f · Cited by 26
Structural Characterization of the CD44 Stem Region for Standard and Cancer-Associated Isoforms
Chen, K., Deng, L., Lu, T.-X., & Chang, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21010336 · Cited by 26
Xue, H.-G., Yang, A., Sun, X., Lu, Y., & Tian, Z. (2016) · Medical Science Monitor · doi:10.12659/msm.896225 · Cited by 24
Binmadi, N. O., El-Sissi, A. A., & Elsissi, N. (2016) · Head & Face Medicine · doi:10.1186/s13005-016-0102-4 · Cited by 23
Maisel, D., Birzele, F., Voß, E., Nopora, A., Bader, S., Friess, T., Goller, B., Laifenfeld, D., Weigand, S., & Runza, V. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159716 · Cited by 23
Louhichi, T., Ziadi, S., Saad, H., Dhiab, M. B., Mestiri, S., & Trimèche, M. (2018) · Breast Cancer · doi:10.1007/s12282-018-0875-3 · Cited by 23
Novel prognostic markers within the CD44‐stromal ligand network in pancreatic cancer
Franklin, O., Billing, O., Öhlund, D., Berglund, A., Herdenberg, C., Wang, W., Hellman, U., & Sund, M. (2018) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.122 · Cited by 23
Analysis of CD44 isoform v10 expression and its prognostic value in renal cell carcinoma
Li, N., Tsuji, M., Kanda, K., Murakami, Y., Kanayama, H., & Kagawa, S. (2000) · British Journal of Urology · doi:10.1046/j.1464-410x.2000.00483.x · Cited by 22
Elevated CD44 expression predicts poor prognosis in patients with low‑grade glioma
Dong, Q., Li, Q., Wang, M., Hu, J., Dai, J., Niu, L., Yuan, G., & Pan, Y. (2019) · Oncology Letters · doi:10.3892/ol.2019.10728 · Cited by 21
Cho, J.-H., Lee, S.-C., Ha, N., Lee, S.-J., & Yoon, M. (2015) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2015.05.014 · Cited by 19
Mirzaei, A., Mohammadi, S., Ghaffari, S. H., Yaghmaie, M., Vaezi, M., Alimoghaddam, K., & Ghavamzadeh, A. (2018) · Europe PMC (PubMed Central) · doi:10.22034/apjcp.2018.19.3.615 · Cited by 18
Hypoxia induces differential expression patterns of osteopontin and CD44 in colorectal carcinoma
Wohlleben, G., Hauff, K., Gasser, M., Waaga-Gasser, A. M., Grimmig, T., Flentje, M. P., & Polat, B. ⁄. L. (2017) · Oncology Reports · doi:10.3892/or.2017.6068 · Cited by 17
The interaction between aromatase, metalloproteinase 2,9 and cd44 in breast cancer
Bagnoli, F., de Oliveira, V. M., da Silva, M. A. L. G., Taromaru, G. C. M., Rinaldi, J. F., & Aoki, T. (2010) · Revista da Associação Médica Brasileira · doi:10.1590/s0104-42302010000400023 · Cited by 15
Mishra, A. K., Sriram, H., Chandarana, P., Tanavde, V., Kumar, R. V., Gopinath, A., Govindarajan, R., Ramaswamy, S., & Sadasivam, S. (2018) · Tumor Biology · doi:10.1177/1010428318780859 · Cited by 14
Wattanawongdon, W., Simawaranon, T., & Tongtawee, T. (2019) · Europe PMC (PubMed Central) · Cited by 11
Cited by
Wang, S., Wang, J., Chen, Z., Luo, J., Guo, W., Sun, L., & Lin, L. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00522-z · Cited by 569
Cancer stem cells: advances in knowledge and implications for cancer therapy
Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01851-y · Cited by 553
CD44 connects autophagy decline and ageing in the vascular endothelium
Zhang, L., Yang, P., Chen, J., Chen, Z., Liu, Z., Feng, G., Sha, F., Li, Z., Xu, Z., Huang, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41346-y · Cited by 45
Osteopontin in Cancer: Mechanisms and Therapeutic Targets
Kariya, Y., & Kariya, Y. (2022) · International Journal of Translational Medicine · doi:10.3390/ijtm2030033 · Cited by 14
Guo, W., Gou, X., Yu, L., Zhang, Q., Yang, P., Pang, M., Pang, X., Pang, C., Wei, Y., & Zhang, X. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1129470 · Cited by 10
Metadata
- Authors
- Hassn Mesrati, M., Syafruddin, S. E., Mohtar, M. A., & Syahir, A.
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2021-12-09
- Volume
- 11
- Issue
- 12
- Pages
- 1850
- ISSN
- 2218-273X (ISSN-L)
- OpenAlex
- W4200191473
- Cited by
- 492
- References
- 189
- FWCI
- 29.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.